Live Analyst Rating Changes 35090 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Xian Deng
UBS

Xian Deng

UBS
Wall Street Analyst
★★☆☆☆
#2365
on 13Foresight · ranked by our own returns
43%
Success Rate
+4.8%
Average Return
6 of 14 calls profitable · +27.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 43% of Xian Deng's ratings turned a profit when each position was held for 1 year — averaging +4.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

23 Buy 17 Hold 0 Sell
Xian's Stock Coverage 14 ratings · 2026-09-28
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
MX:HLUNBN
H. Lundbeck A/S Class B
 Sep 21, 2026 BUY Sell
2 analysts
$140.08
 · ·
CH:BIOV
BioVersys AG
 Sep 10, 2026 BUY Strong Buy
+66.0% avg upside
2 analysts
$47.00
79.32% Upside
 -3.7% ·
GB:0QW0
arGEN X
 Aug 26, 2026 BUY Strong Buy
-25.2% avg upside
25 analysts
 — · ·
ARGX
Argenx Se
 Aug 26, 2026 BUY Strong Buy
-13.5% avg upside
48 analysts
$1400.00
45.94% Upside
 -8.2% ·
GB:0MGB
Genmab A/S
 Aug 07, 2026 BUY Buy
-7.6% avg upside
25 analysts
$2700.00
18.48% Upside
 · ·
GB:0NZT
UCB SA
 Aug 04, 2026 BUY Strong Buy
+4.0% avg upside
19 analysts
$310.00
44.53% Upside
 · ·
FR:IPN
Ipsen
 Aug 03, 2026 HOLD Hold
-12.1% avg upside
17 analysts
$170.00
18.65% Upside
 -8.7% ·
ZLDPF
Zealand Pharma
 May 08, 2026 BUY Buy
+90.5% avg upside
12 analysts
$111.23
164.99% Upside
 -21.5% ·
NL:LKFT
Lakefront Biotherapeutics NV
 Apr 01, 2026 HOLD Sell
+96.5% avg upside
17 analysts
$30.00
15.51% Upside
 +1.5% ·
CH:LONN
Lonza Group Ltd
 Feb 06, 2023 BUY Strong Buy
+13.7% avg upside
21 analysts
$605.00
6.19% Upside
 -20.6% ·
DE:MDG1
Medigene
 Aug 04, 2022 BUY Buy
+79899.9% avg upside
2 analysts
$8.00
79899.92% Upside
 · ·
GB:0FWY
SalMar ASA
 May 26, 2020 HOLD Hold
-6.2% avg upside
5 analysts
$450.00
22.56% Downside
 +49.1% ·
GB:0OAW
Mowi ASA
 Feb 17, 2020 BUY Strong Buy
+13.3% avg upside
6 analysts
$255.00
24.33% Upside
 -13.7% ·
NL:CRBN
Corbion NV
 Nov 01, 2019 BUY Strong Buy
+41.7% avg upside
7 analysts
$31.00
38.30% Upside
 +56.5% ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Xian Deng — Frequently Asked Questions
How accurate are Xian Deng's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Xian's ratings were profitable over a one-year hold, with an average return of +4.8% per rating, or +27.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Xian ranked on 13Foresight?
Xian Deng is currently ranked #2365 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Xian cover?
Xian most recently has ratings on MX:HLUNBN, CH:BIOV, GB:0QW0, ARGX, GB:0MGB, GB:0NZT, FR:IPN, ZLDPF, NL:LKFT, CH:LONN, DE:MDG1, GB:0FWY and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.